Health benefits of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults

Journal of Dairy Science

Volumn 98, Issue 4, 2015, Pages 2277-2283

  Gomi, A ^a   Iino, T ^a   Nonaka, C ^a   Miyazaki, K ^a   Ishikawa, F ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Bifidobacterium bifidum; Fermented milk; Gastric symptoms; Questionnaire

Indexed keywords

BIFIDOBACTERIUM BIFIDUM;

PROBIOTIC AGENT;

ADULT; AGED; ANIMAL; BIFIDOBACTERIUM; CLINICAL TRIAL; CROSSOVER PROCEDURE; DAIRY PRODUCT; DOUBLE BLIND PROCEDURE; FEMALE; FERMENTATION; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMAN; INTESTINE FLORA; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; QUESTIONNAIRE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIFIDOBACTERIUM; CROSS-OVER STUDIES; DAIRY PRODUCTS; DOUBLE-BLIND METHOD; FEMALE; FERMENTATION; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; PROBIOTICS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84925335233     PISSN: 00220302     EISSN: 15253198     Source Type: Journal    
DOI: 10.3168/jds.2014-9158     Document Type: Article

References (31)

1. Agrawal A., Houghton L.A., Morris J., Reilly B., Guyonnet D., Goupil Feuillerat N., Schlumberger A., Jakob S., Whorwell P.J. Clinical trial: The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 2009, 29:104-114.
2. Boivin M. Socioeconomic impact of irritable bowel syndrome in Canada. Can. J. Gastroenterol. 2001, 15(Suppl. B):8B-11B.
3. Cain A.M., Karpa K.D. Clinical utility of probiotics in inflammatory bowel disease. Altern. Ther. Health Med. 2011, 17:72-79.
4. Fujimoto J., Watanabe K. Quantitative detection of viable Bifidobacterium bifidum BF-1 cells in human feces by using propidium monoazide and strain-specific primers. Appl. Environ. Microbiol. 2013, 79:2182-2188.
5. Fuller R. Probiotics in human medicine. Gut 1991, 32:439-442.
6. Gomi A., Harima-Mizusawa N., Shibahara-Sone H., Kano M., Miyazaki K., Ishikawa F. Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model. J. Dairy Sci. 2013, 96:832-837.
7. Horvath A., Dziechciarz P., Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment. Pharmacol. Ther. 2011, 33:1302-1310.
8. Isolauri E., Sutas Y., Kankaanpaa P., Arvilommi H., Salminen S. Probiotics: Effects on immunity. Am. J. Clin. Nutr. 2001, 73(Suppl.):444S-450S.
9. Kamino D., Manabe N., Hata J., Haruma K., Tanaka S., Chayama K. Long-term ultrasonographic follow-up study of gastric motility in patients with functional dyspepsia. J. Clin. Biochem. Nutr. 2008, 42:144-149.
10. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
11. Matsumoto Y., Ito M., Kamino D., Tanaka S., Haruma K., Chayama K. Relation between histologic gastritis and gastric motility in Japanese patients with functional dyspepsia: Evaluation by transabdominal ultrasonography. J. Gastroenterol. 2008, 43:332-337.
12. Mayer E.A. Clinical practice. Irritable bowel syndrome. N. Engl. J. Med. 2008, 358:1692-1699.
13. Miki K., Urita Y., Ishikawa F., Iino T., Shibahara-Sone H., Akahoshi R., Mizusawa S., Nose A., Nozaki D., Hirano K., Nonaka C., Yokokura T. Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans. J. Dairy Sci. 2007, 90:2630-2640.
14. Miyazaki K., Matsuzaki T. Health properties of milk fermented with Lactobacillus casei strain Shirota (LcS). Handbook of Fermented Functional Foods 2008, 165-208. CRC Press, Boca Raton, FL.
15. Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx-Orenstein A.E., Brandt L.J., Quigley E.M. The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. Gut 2010, 59:325-332.
16. Nagaoka M., Hashimoto S., Watanabe T., Yokokura T., Mori Y. Anti-ulcer effects of lactic acid bacteria and their cell wall polysaccharides. Biol. Pharm. Bull. 1994, 17:1012-1017.
17. Quigley E.M., Locke G.R., Mueller-Lissner S., Paulo L.G., Tytgat G.N., Helfrich I., Schaefer E. Prevalence and management of abdominal cramping and pain: A multinational survey. Aliment. Pharmacol. Ther. 2006, 24:411-419.
18. Reid G., Hammond J.A. Probiotics. Some evidence of their effectiveness. Can. Fam. Physician 2005, 51:1487-1493.
19. Saad R.J., Chey W.D. Review article: Current and emerging therapies for functional dyspepsia. Aliment. Pharmacol. Ther. 2006, 24:475-492.
20. Sakamoto I., Igarashi M., Kimura K., Takagi A., Miwa T., Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrob. Chemother. 2001, 47:709-710.
21. Sgouras D., Maragkoudakis P., Petraki K., Martinez-Gonzalez B., Eriotou E., Michopoulos S., Kalantzopoulos G., Tsakalidou E., Mentis A. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ. Microbiol. 2004, 70:518-526.
22. Shirasawa Y., Shibahara-Sone H., Iino T., Ishikawa F. Bifidobacterium bifidum BF-1 suppresses Helicobacter pylori-induced genes in human epithelial cells. J. Dairy Sci. 2010, 93:4526-4534.
23. Svedlund J., Sjodin I., Dotevall G. GSRS-A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 1988, 33:129-134.
24. Sykora J., Valeckova K., Amlerova J., Siala K., Dedek P., Watkins S., Varvarovska J., Stozicky F., Pazdiora P., Schwarz J. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: A prospective randomized double-blind study. J. Clin. Gastroenterol. 2005, 39:692-698.
25. Tack J., Talley N.J., Camilleri M., Holtmann G., Hu P., Malagelada J.R., Stanghellini V. Functional gastroduodenal disorders. Gastroenterology 2006, 130:1466-1479.
26. Talley N.J., Vakil N. Guidelines for the management of dyspepsia. Am. J. Gastroenterol. 2005, 100:2324-2337. and Practice Parameters Committee of the American College of Gastorenterology.
27. Umesaki Y., Matsumoto K., Asahara T., Onoue M., Kawakami K., Nanno M., Shida K., Matsumoto S., Ishikawa F., Iino T., Sawada H., Shima T., Ishikawa E., Imaoka A., Takahashi T., Morotomi M., Nomoto K. Health-Promoting Effects of B. breve strain Yakult and B. bifidum strain Yakult. Advances in the Science of Bifidobacterium Yakult Strains-Intestinal Microbiota and Human Health 2012, 145-298. Yakult Central Institute for Microbiological Research, Yakult Honsha Co. Ltd, Tokyo, Japan.
28. Urita Y., Watanabe T., Maeda T., Sasaki Y., Sugimoto M., Ishikawa F., Iino T., Shibahara-Sone H., Akahori R., Mizusawa S., Nose A., Nozaki D., Hirano K., Nonaka C., Yokokura T. O040 Bifidobacterium bifidum fermented milk enhances gastric emptying. Clin. Nutr. Suppl. 2008, 1:19.
29. Waller P.A., Gopal P.K., Leyer G.J., Ouwehand A.C., Reifer C., Stewart M.E., Miller L.E. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand. J. Gastroenterol. 2011, 46:1057-1064.
30. Watanabe T., Urita Y., Sugimoto M., Miki K. Gastroesophageal reflux disease symptoms are more common in general practice in Japan. World J. Gastroenterol. 2007, 13:4219-4223.
31. Yamamoto Y., Sakurabayashi S., Abe K., Sezai S., Hirano M., Oka H. Anti-ulcer effect of Bifidobacterium bifidum YIT 4007. Japan. Pharmacol. Therapeut. 1994, 22:4743-4746.